Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study

dc.contributor.author	Eraksoy, M.
dc.contributor.author	O'Neill, G. N.
dc.contributor.author	Yang, M.
dc.contributor.author	Meluzinova, E.
dc.contributor.author	Rektor, I.
dc.contributor.author	Gold, R.
dc.contributor.author	Havrdova, E.
dc.contributor.author	Kappos, L.
dc.contributor.author	Limmroth, V.
dc.contributor.author	Miller, D.
dc.contributor.author	Polman, C.
dc.date.accessioned	2021-03-04T17:37:00Z
dc.date.available	2021-03-04T17:37:00Z
dc.identifier.citation	Gold R., Havrdova E., Kappos L., Limmroth V., Miller D., Polman C., Yang M., Eraksoy M., Meluzinova E., Rektor I., et al., "Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study", 16th Annual Meeting of the European-Neurological-Society, Lausanne, İsviçre, 27 - 31 Mayıs 2006, cilt.253, ss.144-145
dc.identifier.other	vv_1032021
dc.identifier.other	av_866e5353-021c-4c19-8c78-0c199b5920fd
dc.identifier.uri	http://hdl.handle.net/20.500.12627/91352
dc.language.iso	eng
dc.subject	Sağlık Bilimleri
dc.subject	Dahili Tıp Bilimleri
dc.subject	Nöroloji
dc.subject	Klinik Tıp (MED)
dc.subject	Tıp
dc.subject	Klinik Tıp
dc.subject	KLİNİK NEUROLOJİ
dc.title	Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study
dc.type	Bildiri
dc.contributor.department	, ,
dc.identifier.volume	253
dc.contributor.firstauthorID	131844

Bu öğenin dosyaları:

Dosyalar	Boyut	Biçim	Göster
Bu öğe ile ilişkili dosya yok.